
Release date: 2026-05-12 16:35:35 Article From: Lucius Laos Recommended: 6
Maintaining good nutrition is essential during treatment for metastatic breast cancer. A well-balanced diet helps the body preserve muscle strength, promotes tissue repair from treatment-related damage, and supports immune system function. Specific recommendations include: prioritizing high-quality protein sources such as fish, poultry, and soy products; consuming adequate fruits and vegetables for vitamins and antioxidants; and adopting small, frequent meals to manage potential appetite loss or nausea. Adequate fluid intake should not be overlooked, especially in the event of diarrhea or vomiting. It is important to consult your healthcare provider or a registered dietitian before making any dietary changes or starting a new exercise program. They can develop an individualized nutrition plan based on your specific treatment regimen, current weight, laboratory parameters (e.g., blood cell counts, liver and kidney function), and personal preferences. Good nutrition is not a substitute for treatment, but an important part of helping you tolerate therapy and improve your quality of life.
For patients with severe hepatic impairment (Child-Pugh Class C), the recommended dose of IBRANCE should be reduced from 125 mg to 75 mg. Pharmacokinetic studies have not been conducted in patients requiring hemodialysis, so caution should be exercised when using it in such patients. With regard to drug interactions, aside from avoiding strong CYP3A inhibitors/inducers, IBRANCE tablets can be coadministered with proton pump inhibitors (PPIs) or antacids, which provides convenience for patients with concomitant gastric acid-related disorders.
May be taken with or without food. If a patient vomits or misses a dose, the dose should not be taken later that day; simply take the next prescribed dose at the usual time. Do not take tablets that are broken, cracked, or appear incomplete. All dosage forms should be stored at 68°F to 77°F (20°C to 25°C), and tablets must be kept in the original blister packaging.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3262025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5382024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3182025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3342025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3082025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3622025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3052025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2852025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: